1 2026 CORPORATE GOVERNANCE STATEMENT The Board of Vitrafy Life Sciences Limited ( Company or Vitrafy ) is responsible for the Company’s overall corporate governance framework. The Board recognises the importance of good corporate governance and its role in ensuring the...
FY26 Corporate Governance Statement
Filed with ASX ·
6ix hasn’t read this filing yet.
Vitrafy Life Sciences Ltd. on 6ix
In the deck
Earlier from Vitrafy Life Sciences
- FY26 Appendix 4G
- Vitrafy FY26 Investor Briefing
- Q4 FY26 Quarterly Activities Report and Appendix 4C
- Vitrafy enters a partnership with Hoxworth Blood Center
- Vitrafy Share Purchase Plan Opens - SPP Offer Booklet
Later from Vitrafy Life Sciences
- FY26 Appendix 4E and Annual Report
- FY26 Full Year Results Presentation
- Vitrafy enters U.S. Cell & Gene Therapy Market
- S&P DJI Announces September 2026 Quarterly Rebalance
- Vitrafy enters partnership with Versiti Blood Health
Follow Vitrafy Life Sciences into a list and get an email when it puts out news.
Follow Vitrafy Life Sciences